Dr. Scott Rocklage is a Founding Partner at 5AM Venture Management LLC; a life science-based venture capital organization. For over three decades, he has been involved in healthcare industry management, research, invention, and investment. He started as a healthcare manager, when he joined 5AM Ventures as a Ventures Partner in 2003, and rose to be a Founding Partner. Concurrently, he serves as Chairman of Novira Therapeutics Inc., and as Director, Rennovia Inc. among other other boards. Prior to becoming Founding Partner at 5AM Ventures, he served as President and Chairman of Nycomed Salutar, and as Chief Executive Officer at Epirus Biopharmaceuticals, Inc. until May, 2016.
He has worked collaboratively to find a cure for the treatment of diseases caused by Ribonucleic Acid (RNA), such as the Myotonic Dystrophy type 1, which is a debilitating, hereditary disease responsible for muscular dysfunction (DMI) in adults. This disease defies known medical treatment, it is triggered when certain types of RNAs inside the cells increasingly rise to levels of toxicity and cause breakdown of the body’s central nervous system and muscles. Dr. Rocklage’s interest in this type of medical research came to the fore when he engaged in research in the laboratory of Richard Schrock; the 2005 Chemistry Nobel Prize winner. His career pursuit led him to become an accomplished co-inventor and the inventor of over 30 US patents, and also made him the focus of over 100 peer-reviewed professional publications.
His dynamic leadership was instrumental to FDA’s approval of three therapeutic drugs – Cubicin, Teslascan and Omniscan,, and presentation of numerous clinical trials. As an entrepreneur, he believes in hard work, commitment, an effective team and measured risk-taking,. His work in life-saving science research has aimed to save lives. This has been influenced by his interactions with business professionals, scientists, and physicians, with whom he shared ideas to create potential medicines for treating challenging medical conditions. Scott Rocklage has entrenched himself as a new-breed investor, bringing finance and his over three-decade experience in healthcare management to bear on healthcare industry investments.
In collaboration with Sanofi Ventures, Kleiner Perkings, and Novartis Venture, Dr. Rocklage is currently helping Dr. Matthew Disney of Expansion Therapeutics, who has discovered a cure using small molecular medications in the treatment of DMI, to secure Series A funding for his work. Rocklage’s group, which has secured over $55 million, is working hard to get financing for life science research, the pharmaceutical companies, and to make treatment accessible to the needy.
Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.